ZyVersa Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

ZyVersa Therapeutics' CEO is Steve Glover, appointed in Dec 2022, has a tenure of 1.92 years. total yearly compensation is $993.22K, comprised of 55.4% salary and 44.6% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $2.74K. The average tenure of the management team and the board of directors is 1.9 years and 1.9 years respectively.

Anahtar bilgiler

Steve Glover

İcra Kurulu Başkanı

US$993.2k

Toplam tazminat

CEO maaş yüzdesi	55.4%
CEO görev süresi	1.9yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	1.9yrs
Yönetim Kurulu ortalama görev süresi	1.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Steve Glover'un ücretlendirmesi ZyVersa Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$22m
Mar 31 2024	n/a	n/a	-US$106m
Dec 31 2023	US$993k	US$550k	-US$106m
Sep 30 2023	n/a	n/a	-US$88m
Jun 30 2023	n/a	n/a	-US$98m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$1m	US$451k	-US$14m
Sep 30 2022	n/a	n/a	-US$21m
Jun 30 2022	n/a	n/a	-US$10m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	US$2m	US$451k	-US$8m
Dec 31 2020	US$451k	US$451k	-US$13m

Tazminat ve Piyasa: Steve's total compensation ($USD993.22K) is above average for companies of similar size in the US market ($USD655.65K).

Tazminat ve Kazançlar: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Glover (64 yo)

1.9yrs

Görev süresi

US$993,217

Tazminat

Mr. Stephen C. Glover, also known as Steve, serves as Chairman of the Board at Ambrx Biopharma Inc. since May 18, 2023. He has been a Director of Incon Co., Ltd. since December 2018.Mr. Glover is a Co-Fou...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen Glover	Co-Founder	1.9yrs	US$993.22k	0.13% $ 2.7k
Peter Wolfe	CFO & Secretary	1.9yrs	US$573.36k	0.012% $ 244.6
Karen Cashmere	Chief Commercial Officer	1.9yrs	US$486.69k	0% $ 0
Melda Uzbil O'connell	Senior Vice President of Corporate Development	no data	Veri yok	Veri yok
Pablo Guzman	Chief Medical Officer	1.8yrs	Veri yok	0.0071% $ 145.3

1.9yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim: ZVSA's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephen Glover	Co-Founder	1.9yrs	US$993.22k	0.13% $ 2.7k
Pablo Guzman	Chief Medical Officer	no data	Veri yok	0.0071% $ 145.3
Gregory Freitag	Independent Director	1.8yrs	US$80.14k	0% $ 0
Robert Finizio	Independent Director	1.9yrs	US$80.64k	0% $ 0
James Sapirstein	Independent Director	1.8yrs	US$72.90k	0% $ 0
Marlene Haffner	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Alessia Fornoni	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Helen Bramlett	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Juan de Rivero Vaccari	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Keane	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Sharon Adler	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Min-Chul Park	Independent Director	1.9yrs	US$66.39k	0% $ 0

1.9yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ZVSA's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

ZyVersa Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

ZyVersa Therapeutics, Inc. Forms New Scientific Advisory Board

ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 29, 2024

High number of new and inexperienced directors

ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 31, 2023

ZyVersa Therapeutics, Inc. Announces Changes to Board of Directors

ZyVersa Therapeutics, Inc. Appoints Dr. Pablo Guzman as Chief Medical Officer and Senior Vice President of Medical Affairs

Recent updates

ZyVersa Therapeutics, Inc. Forms New Scientific Advisory Board

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.397396 million.

ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 29, 2024

ZyVersa Therapeutics, Inc. Announces Publish Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease

ZyVersa Therapeutics Receives Letter of Reprimand from Nasdaq in Accordance with Nasdaq’s Listing Rule 5810(c)(4)

ZyVersa Therapeutics Receives Approval from Nasdaq to Transfer the Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market

ZyVersa Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.99964 million.

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

High number of new and inexperienced directors

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering.

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering.

ZyVersa Therapeutics, Inc. Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating that Inflammasome ASC Inhibitor IC 100 Attenuates Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection

ZyVersa Therapeutics, Inc. Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease

ZyVersa Therapeutics, Inc. Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues

Zyversa Therapeutics Announces Research Published in the Journal of Clinical Investigation Reinforcing Ic 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues

Zyversa Therapeutics, Inc. Announces Research Published in Frontiers in Immunology Reinforcing Ic 100'S Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases

ZyVersa Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

ZyVersa Therapeutics, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 31, 2023

ZyVersa Therapeutics, Inc. announced delayed 10-Q filing

ZyVersa Therapeutics, Inc. Announces European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™? VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. Announces Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arterial Disease

ZyVersa Therapeutics Receives Non-Compliance Letter Form Nasdaq

European Patent Office to Grant Zyversa Therapeutics' Patent Application for Cholesterol Transport Mediator™? Var 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. Announces Changes to Board of Directors

ZyVersa Therapeutics, Inc. Appoints Dr. Pablo Guzman as Chief Medical Officer and Senior Vice President of Medical Affairs

Less than half of directors are independent

ZyVersa Therapeutics, Inc. Announces Executive Changes

ZyVersa Therapeutics, Inc. Adds Two Esteemed Leaders to Its Renal Scientific Advisory Board

High number of new directors

No independent directors

ZyVersa Therapeutics, Inc. completed the acquisition of Larkspur Health Acquisition Corp. (NasdaqGM:LSPR) from Larkspur Health LLC, A.G.P. / Alliance Global Partners Corp. and others in a reverse merger transaction.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş